VYGR - ボイジャ―・セラピュ―ティクス (Voyager Therapeutics Inc.)

VYGRのニュース

   The Week Ahead In Biotech (Dec. 27-Jan. 2): Data Releases, Regulatory Filings To Move Stocks  2020/12/26 14:15:51 Benzinga
Biotech stocks advanced for a fifth straight week in thin holiday trading. The gains, however, were more modest amid worries concerning the emergence of a new strain of coronavirus in the U.K. The news flow of the week comprised mixed clinical trial readouts, COVID-19 drug and vaccine announcements, a few M&A announcements and a small-ticket IPO. Gene therapy stocks uniQure N.V. (NASDAQ: QURE ) and Voyager Therapeutics, Inc. (NASDAQ: VYGR ) came under pressure after the Food and Drug Administration placed their respective clinical programs on hold. Ocugen Inc (NASDAQ: OCGN ) was some of the big news of the week , with the strength stemming from an agreement to co-develop a vaccine against SARS-CoV-2. Here are the key catalysts for the week ahead: PDUFA Dates Viatris Inc (NASDAQ: VTRS ), which was formed following the merger of the erstwhile generic pharma company Mylan and Pfizer Inc. 's (NYSE: PFE ) Upjohn generic unit, awaits FDA approval for its BLA for MYL-1402O, a proposed biosimilar to Avastin from Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY ).
   Global Gene Therapy Market Report 2020-2030 Featuring Novartis, Bluebird Bio, Spark Therapeutics, Audentes Therapeutics, Voyager Therapeutics, UniQure, Celgene, Cellectis and Sangamo Therapeutics  2020/12/17 17:00:00 PR Newswire
DUBLIN, Dec. 17, 2020 /PRNewswire/ -- The "Gene Therapy Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. Gene Therapy Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and…
   Neurocrine Biosciences Reports Third Quarter 2020 Financial Results  2020/11/09 21:01:00 Benzinga
SAN DIEGO , Nov. 9, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial results for the third quarter ended September 30, 2020 and provided revised full-year 2020 financial expense guidance. "Our focus remains on helping as many patients with tardive dyskinesia as possible and we are adapting to the challenges posed by the pandemic, including the slow recovery of in-person visits with psychiatrists. We are encouraged by recent trends and remain confident in the intermediate and long-term opportunity of INGREZZA to help many more patients with tardive dyskinesia," said Kevin Gorman , Ph.D., Chief Executive Officer of Neurocrine Biosciences. "We are pleased to expand our reach with neurologists with the addition of ONGENTYS to our movement disorder portfolio and continue to advance our development programs focused on neurological, endocrine and psychiatric disorders." Financial Highlights Three Months Ended September 30, Nine Months Ended September 30, (unaudited, in millions, except per share data) 2020 2019 2020 2019 Revenues: Product sales, net $ 254.
   Voyager Therapeutics Announces Third Quarter 2020 Financial Results and Corporate Updates  2020/11/09 21:00:00 GlobeNewswire
CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR) today reported its third quarter 2020 financial results,…
   Voyager Therapeutics Is it time to Buy before this week’s earning report Stock market Insights & financial analysis  2020/11/04 19:19:00 Stock Market Daily
Voyager Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Global Gene Therapy Market Report 2020-2030 Featuring Novartis, Bluebird Bio, Spark Therapeutics, Audentes Therapeutics, Voyager Therapeutics, UniQure, Celgene, Cellectis and Sangamo Therapeutics  2020/12/17 17:00:00 PR Newswire
DUBLIN, Dec. 17, 2020 /PRNewswire/ -- The "Gene Therapy Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. Gene Therapy Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and…
   Neurocrine Biosciences Reports Third Quarter 2020 Financial Results  2020/11/09 21:01:00 Benzinga
SAN DIEGO , Nov. 9, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial results for the third quarter ended September 30, 2020 and provided revised full-year 2020 financial expense guidance. "Our focus remains on helping as many patients with tardive dyskinesia as possible and we are adapting to the challenges posed by the pandemic, including the slow recovery of in-person visits with psychiatrists. We are encouraged by recent trends and remain confident in the intermediate and long-term opportunity of INGREZZA to help many more patients with tardive dyskinesia," said Kevin Gorman , Ph.D., Chief Executive Officer of Neurocrine Biosciences. "We are pleased to expand our reach with neurologists with the addition of ONGENTYS to our movement disorder portfolio and continue to advance our development programs focused on neurological, endocrine and psychiatric disorders." Financial Highlights Three Months Ended September 30, Nine Months Ended September 30, (unaudited, in millions, except per share data) 2020 2019 2020 2019 Revenues: Product sales, net $ 254.
   Voyager Therapeutics Announces Third Quarter 2020 Financial Results and Corporate Updates  2020/11/09 21:00:00 GlobeNewswire
CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR) today reported its third quarter 2020 financial results,…
   Voyager Therapeutics Is it time to Buy before this week’s earning report Stock market Insights & financial analysis  2020/11/04 19:19:00 Stock Market Daily
Voyager Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Neurocrine Biosciences and Voyager Therapeutics Present New Long-Term Three-Year Data Demonstrating that One-Time Treatment with an Investigational Gene Therapy Showed Sustained Improvement in Motor Function in Patients with Parkinson's Disease  2020/09/11 15:32:00 PR Newswire
SAN DIEGO and CAMBRIDGE, Mass., Sept. 11, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Voyager Therapeutics, Inc. (Nasdaq: VYGR) today announced data from PD-1101, a Phase Ib open-label, three-year efficacy and safety study, demonstrating that a one-time treatment…
   Voyager Therapeutics Is it time to Buy before this week’s earning report Stock market Insights & financial analysis  2020/11/04 19:19:00 Stock Market Daily
Voyager Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Neurocrine Biosciences and Voyager Therapeutics Present New Long-Term Three-Year Data Demonstrating that One-Time Treatment with an Investigational Gene Therapy Showed Sustained Improvement in Motor Function in Patients with Parkinson's Disease  2020/09/11 15:32:00 PR Newswire
SAN DIEGO and CAMBRIDGE, Mass., Sept. 11, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Voyager Therapeutics, Inc. (Nasdaq: VYGR) today announced data from PD-1101, a Phase Ib open-label, three-year efficacy and safety study, demonstrating that a one-time treatment…
   The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings  2020/08/09 13:05:25 Benzinga
Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus treatment/vaccine news flow supported the move to the upside. Novavax, Inc.'s (NASDAQ: NVAX ) stretched valuation got further stretched as the shares added about 20% for the week in the wake of its interim Phase 1 readout for its coronavirus vaccine candidate . Bristol-Myers Squibb Co (NYSE: BMY ) reported a beat-and-raise quarter, with the shares receiving further support from a win in the patent lawsuit over its blood thinner Eliquis. The week also saw a medical technology and two biotechs debuting on the Wall Street. Here are the key catalysts for the unfolding week. Conferences BTIG Virtual Biotechnology Conference: Aug. 10-11 Wedbush PacGrow Healthcare Virtual Conference: Aug. 11-12 PDUFA Dates The FDA is said to rule on the NDA filed by Bausch Health Companies Inc (NYSE: BHC ) for EM-100, an investigational therapy for allergic conjunctivitis.
   Voyager Therapeutics : Down 15% on End of AbbVie Collaborations | MarketScreener  2020/08/03 21:06:00 MarketScreener
By Josh Beckerman Voyager Therapeutics Inc. shares fell 15% to $9.62 after hours as the gene therapy company reported the terminations of its tau and alpha-synuclein vectorized antibody… | August 3, 2020
   Voyager Therapeutics to Report Second Quarter 2020 Financial Results and Participate in Upcoming Investor Conferences  2020/08/03 20:30:00 GlobeNewswire
CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on…

calendar